Matt Calistri | Vice President, Investor Relations |
Michel Vounatsos | Chief Executive Officer |
Michael Ehlers | Executive Vice President, Research and Development |
Jeff Capello | Chief Financial Officer |
Michael Yee | Jefferies |
Umer Raffat | Evercore |
Geoff Meacham | Barclays |
Geoffrey Porges | Leerink |
Eric Schmidt | Cowen & Company |
Matthew Harrison | Morgan Stanley |
Alethia Young | Credit Suisse |
Ying Huang | Bank of America/Merrill Lynch |
Chris Raymond | Piper Jaffray |
Robyn Karnauskas | Citigroup |
Terence Flynn | Goldman Sachs |
Cory Kasimov | JPMorgan |
Carter Gould | UBS |
Good morning. My name is Chris and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Fourth Quarter and Year End 2017 Financial Results and Business Update. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session.